Zobrazeno 1 - 10
of 16
pro vyhledávání: '"P. Nico Lelie"'
Publikováno v:
Viruses, Vol 14, Iss 10, p 2263 (2022)
The efficacy of different screening scenarios in reducing hepatitis B virus (HBV) transmission risk as compared to the risk without screening was modeled in 9,337,110 donations from four geographical regions that had been subjected to hepatitis B sur
Externí odkaz:
https://doaj.org/article/bfe334ec7c084561940559565bd81a1f
Autor:
Harry van Drimmelen, Nico Lelie
Publikováno v:
Viruses, Vol 14, Iss 9, p 1942 (2022)
The Common Specifications/EU 2017/746 regulation for market approval of class D in vitro diagnostic devices (IVDs) intended for detection of blood borne viruses requires testing of the International Standard and 10–30 seroconversion panels to demon
Externí odkaz:
https://doaj.org/article/a04e7584340c44dabc2dad8c058acfd8
Publikováno v:
Journal of Clinical Virology. 47:238-242
Background: Standard preparations for HBsAg are required for quality control of test kits and clinical studies on HBsAg quantitation. WHO provides purified heat inactivated HBsAg diluted in negative defribinated plasma as 2nd International Standard (
Autor:
Henk W. Reesink, Pilar Torres, H. Theo M. Cuypers, R. Garcia De Villaescusa, Michael Chudy, Marco H.G.M. Koppelman, Azzedine Assal, P. Nico Lelie
Publikováno v:
Transfusion. 45:1258-1266
BACKGROUND: The performance of the recently launched Procleix Ultrio (Chiron/Gen-Probe) human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) blood screening assay was evaluated in a European multicenter study.
Autor:
Hans L. Zaaijer, H. Theo M. Cuypers, G. Roosendaal, P. Nico Lelie, Eveline P. Mauser-Bunschoten, H. Marijke van den Berg, Margret Sjerps, M. Damen
Publikováno v:
Blood. 92:2164-2168
The prevalence of hepatitis G virus (HGV)-RNA and HGV-E2 antibodies was studied in a cohort of Dutch hemophilia patients in relation to clotting products used, age, and coinfection with hepatitis C. Between 1991 and 1995, blood samples were taken fro
Autor:
Peter Simmonds, Alfredo Alberti, Harvey J. Alter, Ferruccio Bonino, Daniel W. Bradley, Christian Brechot, Johannes T. Brouwer, Shiu-Wan Chan, Kazuaki Chayama, Ding-Shinn Chen, Qui-Lim Choo, Massimo Colombo, H. Theo M. Cuypers, Takayasu Date, Geoff M. Dusheiko, Juan I. Esteban, Oscar Fay, S. J. Hadziyannis, Jang Han, Angelos Hatzakis, Eddie C. Holmes, Hak Hotta, Michael Houghton, Bruce Irvine, Michinori Kohara, Janice A. Kolberg, George Kuo, Johnson Y. N. Lau, P. Nico Lelie, Geert Maertens, Fiona McOmish, Tatsuo Miyamura, Masashi Mizokami, Akio Nomoto, Alfred M. Prince, Henk W. Reesink, Charlie Rice, Michael Roggendorf, Solko W. Schalm, Toshio Shikata, Kunitada Shimotohno, Lieven Stuyver, Christian Trépo, Amy Weiner, Peng L. Yap, Mickey S. Urdea
Publikováno v:
Hepatology. 19:1321-1324
Autor:
Ed Bakker, Patricia J. van Exel-Oehlers, P. Nico Lelie, Irene Winkel, Jean-Pierre Allain, Cees L. van der Poel, Larry Minims, David S. Vallari, H. Theo M. Cuypers, Henk W. Reesink
Publikováno v:
Journal of medical virology, 37(3), 203-209. Wiley-Liss Inc.
A semiautomated dot blot assay and cDNA polymerase chain reaction (PCR) were used to study longitudinal anti-hepatitis C virus (HCV) recognition patterns in relation to presence of HCV-RNA in transfusion recipients and their infectious donors. In 9 r
Autor:
Marco H G M, Koppelman, Azzedine, Assal, Michael, Chudy, Pilar, Torres, R Garcia, de Villaescusa, Henk W, Reesink, P Nico, Lelie, H Theo M, Cuypers
Publikováno v:
Transfusion. 45(8)
The performance of the recently launched Procleix Ultrio (Chiron/Gen-Probe) human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) blood screening assay was evaluated in a European multicenter study.Serial diluti
Autor:
Henk W. Reesink, Margret Sjerps, M Hans J Molijn, Ton P W Peeters, Cees L. van der Poel, Geert A H Peeters, J.M. Jongerius, Harry van Drimmelen, P. Nico Lelie, H. Theo M. Cuijpers
Publikováno v:
Transfusion, 42(6), 792-797. Wiley-Blackwell
BACKGROUND : Routine HCV NAT minipool screening (48 donations) of all blood donations was implemented in July 1999 and was combined with HIV NAT in November 2000. This report describes the validation of the NAT methods and the results of quality cont
Publikováno v:
Transfusion. 42(5)
BACKGROUND: Blood transfusion centers around the world have introduced minipool NAT to reduce the risk of HBV, HCV, and HIV transmission by blood donations drawn in the infectious window phase. What would be the reduction in the residual risk when mi